NCT03477396View on ClinicalTrials.gov

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

September 29, 2021

Study Completion Date

June 5, 2023

Conditions
Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

Aromatase Inhibitor

Aromatase inhibitor per treating investigator's discretion

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacokinetic Study

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ribociclib

Given PO

Trial Locations (9)

14263

Roswell Park Cancer Institute, Buffalo

14642

Wilmot Cancer Institute, Rochester

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91345

City of Hope Mission Hills, Mission Hills

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03477396 - Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter